Capital Fund Management S.A. Purchases New Shares in Halozyme Therapeutics, Inc. $HALO

Capital Fund Management S.A. purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 107,911 shares of the biopharmaceutical company’s stock, valued at approximately $5,614,000.

A number of other institutional investors have also recently bought and sold shares of the business. Redhawk Wealth Advisors Inc. grew its position in Halozyme Therapeutics by 14.8% during the second quarter. Redhawk Wealth Advisors Inc. now owns 37,419 shares of the biopharmaceutical company’s stock worth $1,947,000 after buying an additional 4,827 shares in the last quarter. Intech Investment Management LLC lifted its position in shares of Halozyme Therapeutics by 9.9% during the 1st quarter. Intech Investment Management LLC now owns 153,199 shares of the biopharmaceutical company’s stock valued at $9,776,000 after acquiring an additional 13,789 shares during the period. Focus Partners Wealth grew its holdings in shares of Halozyme Therapeutics by 57.8% during the 1st quarter. Focus Partners Wealth now owns 120,815 shares of the biopharmaceutical company’s stock worth $7,709,000 after purchasing an additional 44,260 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt increased its position in shares of Halozyme Therapeutics by 78.0% in the second quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 102,000 shares of the biopharmaceutical company’s stock worth $5,305,000 after purchasing an additional 44,700 shares during the period. Finally, Shelton Wealth Management LLC acquired a new position in Halozyme Therapeutics in the second quarter valued at about $843,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Down 1.8%

Shares of HALO stock opened at $71.39 on Monday. Halozyme Therapeutics, Inc. has a fifty-two week low of $46.26 and a fifty-two week high of $79.50. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. The stock has a 50 day simple moving average of $69.25 and a two-hundred day simple moving average of $63.96. The company has a market cap of $8.39 billion, a P/E ratio of 16.34, a PEG ratio of 0.35 and a beta of 1.18.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, topping the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company had revenue of $354.26 million during the quarter, compared to the consensus estimate of $339.18 million. During the same quarter last year, the firm posted $1.27 EPS. The company’s quarterly revenue was up 22.1% on a year-over-year basis. Research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $68.48, for a total value of $136,960.00. Following the completion of the sale, the director directly owned 42,952 shares of the company’s stock, valued at $2,941,352.96. The trade was a 4.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $69.13, for a total value of $1,382,600.00. Following the transaction, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $50,721,994.47. This trade represents a 2.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 110,227 shares of company stock valued at $8,028,955. Corporate insiders own 2.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on HALO shares. Leerink Partners raised shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price target for the company in a report on Tuesday, October 14th. Benchmark lifted their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Morgan Stanley reduced their price objective on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research note on Monday, October 20th. The Goldman Sachs Group upped their target price on Halozyme Therapeutics from $54.00 to $56.00 and gave the company a “neutral” rating in a report on Tuesday, November 18th. Finally, Leerink Partnrs upgraded shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 14th. Seven research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $75.10.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.